The antimicrobial treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections has become a great challenge for medical staff all over the world. Increasing numbers of MDR A. baumannii infections have been identified and reported, but effective clinical treatments for them are decreasing. The objective of this study was to investigate the in vitro activities of combinations of rifa...

Clostridium difficile infection (CDI) is known to be associated with prior exposure to many classes of antibiotics. Standard therapy for CDI (i.e., metronidazole and vancomycin) is associated with high recurrence rates. Although tetracycline derivatives such as tetracycline, doxycycline or tigecycline are not the standard therapeutic choices for CDI, they may serve as an alternative or a compon...

Tigecycline, a novel, first-in-class glycylcycline antibiotic, has been approved for the treatment of complicated intra-abdominal infections and complicated skin and skin structure infections. The pharmacokinetics, metabolism, and excretion of [C]tigecycline were examined in healthy male volunteers. Tigecycline has been shown to bind to bone; thus, to minimize the amount of radioactivity bindin...

he US Food and Drug Administration (FDA) have issued a arning describing increased mortality risk associated with he use of tigecycline when compared to other drugs in the reatment of serious infections. Such increased risk was deterined using a pooled analysis of randomized clinical trials hich involved predominantly patients treated for ventilatorssociated pneumonia (VAP).1 In the present obs...

Carbapenem-resistant Acinetobacter baumannii is increasing in prevalence. Polymyxin B and tigecycline are among the most active antibiotics used against this pathogen in vitro. Past in vitro studies, however, neglected the importance of simulating exposures observed in humans to determine their antibacterial effects. In this study, four carbapenem-resistant A. baumannii isolates were evaluated ...

PURPOSE Tigecycline is one of the drugs used to treat multi-drug resistant Klebsiella pneumoniae (K. pneumoniae) infections, including complicated skin and soft tissue infections, complicated intra-abdominal infection, and community-acquired pneumonia in the Republic of Korea. However, since its commercial release, K. pneumoniae resistance against tigecycline has been reported, and there is a s...

after launch, 61% of the tigecycline prescriptions were ’off label’, especially for patients with ventilator-associated pneumonia (VAP) due to MDR Acinetobacter spp. (D. Curcio, F. Fernández and F. Duret, unpublished data). The high concentration in alveolar cells (77.5-fold higher than serum), the increase in carbapenem-resistant Acinetobacter spp. in Argentina (54%), the lack of medical evide...

Tigecycline, a glycylcycline, is a semisynthetic derivative of minocycline with a broad spectrum of activity against aerobic and anaerobic bacteria (2, 12, 16). In the literature there are several publications concerning tigecycline activity, most of them related to Acinetobacter baumannii and Stenotrophomonas maltophilia isolates (1, 5, 8, 10, 11, 14); however, its activity against other speci...

Severe Clostridium difficile infection is associated with a high rate of mortality; however, the optimal treatment for severe- complicated infection remains uncertain for patients who are not candidates for surgical intervention. Thus, we sought to evaluate the benefit of adjunctive tigecycline in this patient population using a retrospective cohort adjusted for propensity to receive tigecyclin...

We performed a nested case-control study (ratio of 1:4) on the emergence of tigecycline-resistant multidrug-resistant Klebsiella pneumoniae (TR-MDRKP) isolates among patients who initially presented with a tigecycline-susceptible MDRKP isolate. Out of 260 patients, 24 (9%) had a subsequent clinical culture positive for a TR-MDRKP isolate within the 90-day follow-up period. On logistic regressio...